Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported a mix of share sales and new equity awards. He sold a total of 4,068 ordinary shares in open-market transactions at $29.29 and $29.76 per share under a pre-arranged Rule 10b5-1 trading plan and held 235,626 shares after the latest sale. He also received a grant of 78,292 stock options and 36,364 restricted stock units, which vest in four equal annual installments starting on March 2, 2027.
Alkermes plc receipt of a Rule 144 notice indicates a proposed sale of 2,034 shares of common stock. The filing lists the issuer as Alkermes plc, the filer name David Gaffin, and a transaction date of 03/03/2026 on NASDAQ.
The filing also lists vesting entries for restricted stock unit and performance share unit awards dated 03/03/2017, 03/03/2018, 05/28/2015, and 10/05/2015, and notes a prior sale by the filer on 03/02/2026.
Alkermes plc submitted a Rule 144 notice reporting 6,000 shares of Common Stock to be sold with an aggregate price of $180,000.00; the filing lists beneficial ownership of 166,649,934 shares as of 03/02/2026. The filing also lists recent vesting of restricted stock units: 897 on 02/23/2025, 3,952 on 02/22/2025, and 1,151 on 02/18/2025.
Alkermes plc submitted a Form 144 reporting an intended sale of Common Stock on 03/02/2026 in connection with NASDAQ‑listed shares. The filing lists restricted stock unit vestings from 03/03/2017 (322 shares) and 02/17/2018 (1,712 shares) as sources of the shares.
Alkermes plc reported an insider Form 144 filing showing intended dispositions of ordinary shares by a reporting person and multiple recent sales. The filing lists proposed sales/exercises on 03/02/2026 and vesting on 02/05/2026, and records past sales by Craig Hopkinson totaling multiple transactions in Dec 2025–Feb 2026.
The entries include broker-assisted cashless exercise transactions of 5,000 shares and a performance-vesting of 4,000 shares; several open-market sales by Craig Hopkinson are listed with individual share counts and proceeds.
Alkermes plc vice president of finance Samuel Joseph Parisi reported equity transactions involving restricted stock units and ordinary shares. On February 26, 2026, he acquired 2,747 ordinary shares through the exercise/conversion of a restricted stock unit award, with each unit representing one ordinary share. Following this, a separate transaction disposed of 808 ordinary shares at $30.73 per share to cover tax obligations, leaving him with 14,607 ordinary shares held directly. The underlying restricted stock unit award vests in four equal annual installments beginning on February 26, 2025.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units and ordinary shares. On 2026-02-26, he exercised 5,410 restricted stock units, which converted into 5,410 ordinary shares at a stated price of $0.0000 per share.
A related Form 4 line shows 2,403 ordinary shares disposed of at $30.73 per share in a code F transaction, which reflects shares withheld to satisfy tax obligations rather than an open-market sale. After these transactions, Nichols directly owned 115,769 ordinary shares and held 10,819 restricted stock units, each representing a contingent right to receive one ordinary share. The restricted stock unit award vests in four equal annual installments beginning on 02/26/2025.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity compensation-related transactions. On February 26, 2026, he acquired 8,322 ordinary shares upon the exercise of a restricted stock unit award, with each unit representing one ordinary share. On the same date, 3,695 ordinary shares were disposed of at $30.73 per share to satisfy tax withholding obligations. Following these transactions, Curtis directly owned 241,308 ordinary shares. The underlying restricted stock units vest in four equal annual installments beginning on February 26, 2025.
Alkermes plc executive Craig C. Hopkinson reported equity award activity involving restricted stock units and ordinary shares. On 2/26/2026, he exercised 6,866 restricted stock units, which converted into 6,866 ordinary shares at a stated price of $0.0000 per share. In a related tax-withholding transaction, 3,049 ordinary shares were disposed of at $30.73 per share to cover tax obligations rather than as an open-market sale. Following these transactions, he directly held 93,389 ordinary shares and 13,732 restricted stock units. Each restricted stock unit represents a contingent right to receive one ordinary share and the award vests in four equal annual installments commencing on 02/26/2025.
Alkermes plc executive David Joseph Gaffin reported equity award activity. On 2/26/2026, he acquired 6,866 restricted stock units and 6,866 ordinary shares through an exercise or conversion of derivative securities. A separate transaction disposed of 3,049 ordinary shares at $30.73 per share to satisfy tax obligations.
After these transactions, Gaffin directly held 13,732 restricted stock units and 239,694 ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments beginning on 2/26/2025.